This report provides a direct comparison of Non-Small Cell Lung Cancer Treatment Options: New Zealand and Australia versus European Society for Medical Oncology (ESMO) Guidelines. Sadly this report demonstrates how far behind Pharmac is with reimbursing standard of care treatments for NZ’s Biggest Cancer Killer and why lung cancer patients die prematurely in New Zealand. […]
“There are more than a hundred medicines on the PHARMAC waiting list. Some have been there five, ten or even fifteen years. I interviewed the Chief Executive of PHARMAC, Sarah Fitt, and asked her whether she was comfortable with that. Well, if there’s other medicines that have come along and replaced it. If there’s not […]
New Zealand is so far behind with access to standard of care treatments it is embarrassing. Lung cancer is the most targetable cancer. However, Pharmac policy is causing our most vulnerable to die prematurely.